专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

EP2935238B1 ARYL AND HETEROARYL FUSED LACTAMS 有权转让
标题翻译： ARYL和HETEROARYL融合内糖
公开(公告)号：EP2935238B1
公开(公告)日：2017-12-27
申请号：EP13817739.9
申请日：2013-12-05
申请人： Pfizer Inc.
发明人： EDWARDS, Martin Paul , KUMPF, Robert Arnold , KUNG, Pei-Pei , MCALPINE, Indrawan James , NINKOVIC, Sacha , RUI, Eugene Yuanjin , SUTTON, Scott Channing , TATLOCK, John Howard , WYTHES, Martin James , ZEHNDER, Luke Raymond
IPC分类号： C07D401/06 , C07D401/14 , C07D413/14 , C07D403/14 , C07D407/14 , C07D413/06 , C07D471/04 , A61P35/00 , A61K31/4725
CPC分类号： C07D401/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/06 , C07D413/14 , C07D471/04 , C07D487/04

32. 发明授权

EP3071557B1 1-ARYL-3-ALKYLPYRAZOLE INSECTICIDES 有权转让
标题翻译： 1-ARYL-3-烷基吡唑杀虫剂
公开(公告)号：EP3071557B1
公开(公告)日：2017-11-01
申请号：EP14810079.5
申请日：2014-11-20
申请人： E. I. du Pont de Nemours and Company
发明人： AHMAD, Omar Khaled , PAHUTSKI JR., Thomas Francis
IPC分类号： C07D401/06 , C07D413/06 , C07D403/06 , C07D401/04 , A01N43/58
CPC分类号： C07D231/12 , A01N25/00 , A01N43/50 , A01N43/56 , C07D401/04 , C07D401/06 , C07D403/06 , C07D405/00 , C07D413/06
摘要： and Z, R1, R2a, R2b, R2c, R2d, J1, J2 and M are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

34. 发明公开

EP3110423A4 ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS 审中-公开
标题翻译： ETHERVERBINDUNGEN ZUR BEHANDLUNG VON KOMPLEMENTVERMITTELTEN ERKRANKUNGEN
公开(公告)号：EP3110423A4
公开(公告)日：2017-09-20
申请号：EP15755233
申请日：2015-02-25
申请人： ACHILLION PHARMACEUTICALS INC
发明人： GADHACHANDA VENKAT RAO , PAIS GODWIN , HASHIMOTO AKIHIRO , WANG QIUPING , CHEN DAWEI , WANG XIANGZHU , AGARWAL ATUL , DESHPANDE MILIND , PHADKE AVINASH S , WILES JASON ALLAN
IPC分类号： C07D401/14 , A61K31/401 , A61K31/416 , A61P37/00 , C07D405/14 , C07D413/14
CPC分类号： C07F9/5728 , A61K9/0014 , A61K9/0019 , A61K9/0048 , A61K9/0053 , A61K31/404 , A61K31/4045 , A61K31/407 , A61K31/4162 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/675 , A61K31/683 , C07B59/002 , C07B2200/05 , C07D209/12 , C07D209/14 , C07D209/30 , C07D209/40 , C07D209/42 , C07D209/44 , C07D209/88 , C07D401/14 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/14 , C07D491/113 , C07D495/04 , C07D513/04 , C07F5/025 , C07F5/027 , C07F7/0812 , C07F9/65583 , C07F9/6561 , C07F9/65616
摘要： Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
摘要翻译：提供了包含式I的补体因子D抑制剂或其药学上可接受的盐或组合物，其中A基团上的R 12或R 13是氨基取代基（R 32）的化合物，使用方法和方法。本文描述的抑制剂靶向因子D并在替代补体途径的早期和必需点抑制或调节补体级联并降低因子D调节经典和凝集素补体途径的能力。本文描述的因子D的抑制剂能够减少已经与某些自身免疫疾病，炎性疾病和神经退行性疾病以及缺血再灌注损伤和癌症相关的补体的过度激活。

35. 发明授权

EP2834234B1 FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 有权
标题翻译：融合CCR2的环戊基拮抗剂
公开(公告)号：EP2834234B1
公开(公告)日：2017-09-13
申请号：EP13716709.4
申请日：2013-04-05
申请人： Janssen Pharmaceutica NV
发明人： WINTERS, Michael P. , BRANUM, Shawn , FAWZY, Nagy E. , KANG, Fu-An , REUMAN, Michael , RUSSELL, Ronald K. , SUI, Zhihua , TELEHA, Christopher A.
IPC分类号： C07D307/937 , C07D309/10 , C07D487/08 , C07D307/84 , C07D405/14 , C07D413/14 , C07D413/06 , C07D471/04
CPC分类号： C07D309/10 , C07D307/84 , C07D307/937 , C07D405/14 , C07D413/06 , C07D413/14 , C07D471/04 , C07D487/08

36. 发明公开

EP3210969A1 KCNQ2-5 CHANNEL ACTIVATOR 有权
标题翻译： KCNQ2-5通道激活器
公开(公告)号：EP3210969A1
公开(公告)日：2017-08-30
申请号：EP15852712.7
申请日：2015-10-23
申请人： ONO Pharmaceutical Co., Ltd.
发明人： YASHIRO, Kentaro , WAKAMATSU, Daisuke , SAITO, Tetsuji
IPC分类号： C07C275/32 , A61K31/17 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/4045
CPC分类号： C07D213/61 , A61K31/17 , A61K31/341 , A61K31/351 , A61K31/381 , A61K31/4045 , A61K31/417 , A61K31/422 , A61K31/4245 , A61K31/426 , A61K31/435 , A61K31/4545 , A61K31/4965 , A61K31/505 , C07C233/26 , C07C233/29 , C07C275/32 , C07C275/40 , C07D209/30 , C07D213/40 , C07D213/74 , C07D233/64 , C07D239/26 , C07D241/12 , C07D271/06 , C07D277/28 , C07D307/52 , C07D309/04 , C07D333/20 , C07D333/28 , C07D413/06
摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
摘要翻译：本发明涉及通式（I）所示的化合物（其中，各基团的定义与说明书中记载的含义相同）。该化合物可用作KCNQ2-5通道相关疾病的预防和/或治疗剂。

37. 发明公开

EP3110418A4 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS 有权转让
标题翻译： ARYL-，HETEROARYL- UND杂环化合物VERBINDUNGEN ZUR BEHANDLUNG VON KOMPLEMENTVERMITTELTEN ERKRANKUNGEN
公开(公告)号：EP3110418A4
公开(公告)日：2017-08-02
申请号：EP15755617
申请日：2015-02-25
申请人： ACHILLION PHARMACEUTICALS INC
发明人： GADHACHANDA VENKAT RAO , WANG QIUPING , PAIS GODWIN , HASHIMOTO AKIHIRO , CHEN DAWEI , WANG XIANGZHU , AGARWAL ATUL , DESHPANDE MILIND , WILES JASON ALLAN , PHADKE AVINASH S
IPC分类号： C07D401/14 , A61K31/401 , A61K31/416 , A61P37/00 , C07D405/14 , C07D413/14
CPC分类号： C07F9/5728 , A61K9/0014 , A61K9/0019 , A61K9/0048 , A61K9/0053 , A61K31/404 , A61K31/4045 , A61K31/407 , A61K31/4162 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/549 , A61K31/55 , A61K31/675 , A61K31/683 , C07B59/002 , C07B2200/05 , C07D209/12 , C07D209/14 , C07D209/30 , C07D209/40 , C07D209/42 , C07D209/44 , C07D209/88 , C07D401/14 , C07D403/06 , C07D403/08 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/14 , C07D491/113 , C07D495/04 , C07D513/04 , C07F5/025 , C07F5/027 , C07F7/0812 , C07F9/65583 , C07F9/6561 , C07F9/65616
摘要： Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
摘要翻译：提供了包含式I的补体因子D抑制剂或其药学上可接受的盐或组合物，其中A基团上的R 12或R 13是氨基取代基（R 32）的化合物，使用方法和方法。本文描述的抑制剂靶向因子D并在替代补体途径的早期和必需点抑制或调节补体级联并降低因子D调节经典和凝集素补体途径的能力。本文描述的因子D的抑制剂能够减少已经与某些自身免疫疾病，炎性疾病和神经退行性疾病以及缺血再灌注损伤和癌症相关的补体的过度激活。

38. 发明公开

EP3176163A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT 有权
标题翻译：新型INDEN衍生物PROCESS其制造和药物组合物，预防和治疗视网膜疾病的，作为ACTIVE
公开(公告)号：EP3176163A1
公开(公告)日：2017-06-07
申请号：EP15827408.4
申请日：2015-07-21
申请人： The Industry & Academic Cooperation in Chungnam National University (IAC)
发明人： KIM, Eunhee , YOO, Sung-Eun , KANG, Nam Sook , KOO, Tae-Sung , PARK, Min-Young , KIM, Young-Hoon , BAE, Hyun-Ju , KIM, Jin-Woo , IN, Tae-Kyu , JOO, Choun-Ki
IPC分类号： C07D413/06 , C07D495/04 , A61K31/5377 , A61P27/02
CPC分类号： C07D495/04 , A23L33/16 , A23L33/40 , A23V2002/00 , A61K31/5377 , C07D209/42 , C07D235/24 , C07D307/85 , C07D333/58 , C07D333/60 , C07D333/74 , C07D409/04 , C07D409/06 , C07D413/06
摘要： The present invention relates to a novel indene derivative, a preparation method for the same, and a pharmaceutical composition for preventing or treating retinal disease comprising the same as an active ingredient. The novel indene derivative of the present invention, the optical isomer of the same, or the pharmaceutically acceptable salts of the same have excellent inhibitory efficiency of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Therefore, the composition containing the same as an active ingredient can be effectively used as a pharmaceutical composition for preventing or treating retinal disease exemplified by retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardts disease, Usher syndrome, choroideremia, rod-cone or cone-rod dystrophy, ciliopathy, mitochondrial disorders, progressive retinal atrophy, degenerative retinal diseases, age-related macular degeneration (AMD), wet AMD, dry AMD, geographical atrophy, inherited or acquired macular degeneration, retinal photoreceptor diseases, retinal pigment epithelial diseases, diabetic retinopathy, cystic macular edema, uveitis, retinal detachment, traumatic retinal injury, iatrogenic retinal injury, macular holes, macular capillarectasia, ganglion cell diseases, optic nerve diseases, glaucoma, optic neuropathy, ischemic retinal diseases, retinopathy of prematurity, occlusion of retinal vessels, inherited macroaneurysm, retinal vascular diseases, ophthalmic vascular diseases, glaucomatous retinal neurodegeneration, ischemic optic neuropathy and the like.
摘要翻译：本发明涉及一种新颖的茚衍生物，对于相同的制备方法，以及用于预防或治疗视网膜疾病，其包括相同的活性成分的药物组合物。本发明的新的茚衍生物，相同的相同的光学异构体，或药学上可接受的盐具有受体相互作用的丝氨酸/苏氨酸 - 蛋白激酶1（RIPK1）的优异的抑制效率。因此，含有相同的活性成分的组合物可以有效地用作预防或治疗由色素性视网膜炎（RP），肝先天性黑蒙（LCA），斯特格氏病，厄舍综合征，无脉络膜，罗德例举视网膜疾病的药物组合物锥或圆锥 - 视杆营养不良，ciliopathy，线粒体疾病，进行性视网膜萎缩，变性视网膜疾病，与年龄相关的黄斑变性（AMD），湿性AMD，干性AMD，地理萎缩，遗传性或获得性黄斑变性，视网膜感光疾病，视网膜色素上皮疾病，糖尿病性视网膜病，囊性黄斑水肿，葡萄膜炎，视网膜脱离，创伤性视网膜损伤，医源性视网膜损伤，黄斑裂孔，黄斑，毛细血管扩张，神经节细胞疾病，视神经疾病，青光眼，视神经病，缺血性视网膜疾病，早产儿视网膜病，视网膜血管，继承大动脉瘤，视网膜血管疾病，OPHT闭塞 halmic血管疾病，视网膜神经变性青光眼，局部缺血性视神经病变等。

40. 发明公开

EP3172192A1 GLUCOSE TRANSPORT INHIBITORS 审中-公开
标题翻译：葡萄糖运输抑制剂
公开(公告)号：EP3172192A1
公开(公告)日：2017-05-31
申请号：EP15748189.6
申请日：2015-07-22
申请人： Bayer Pharma Aktiengesellschaft
发明人： BUCHMANN, Bernd , HEISLER, Iring , MÜLLER, Thomas , CLEVE, Arwed , HÉROULT, Mélanie , NEUHAUS, Roland , PETRUL, Heike , QUANZ-SCHÖFFEL, Maria
IPC分类号： C07D401/12 , C07D401/14 , A61K31/4709 , A61K31/4748 , C07D231/38 , A61K31/415 , A61K31/4155 , A61P35/00 , C07D413/14 , C07D417/14
CPC分类号： C07D401/12 , A61K31/136 , A61K31/337 , A61K31/4709 , A61K31/513 , A61K31/555 , A61K31/573 , A61K31/675 , A61K31/704 , C07D215/50 , C07D231/38 , C07D401/06 , C07D401/14 , C07D403/06 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , A61K2300/00
摘要： The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
摘要翻译：本发明涉及选择性抑制葡萄糖转运蛋白1（GLUT1）的化合物，制备所述化合物的方法，包含所述化合物的药物组合物和组合，涉及所述化合物用于制备用于治疗或预防疾病以及用于制备所述化合物的中间体化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式